IDIOPATHIC PULMONARY FIBROSIS (IPF)
Clinical trials for IDIOPATHIC PULMONARY FIBROSIS (IPF) explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC PULMONARY FIBROSIS (IPF) trials appear
Sign up with your email to follow new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to slow lung scarring and ease cough in IPF patients
Disease control Not yet recruitingThis study tests whether adding dextromethorphan to the standard drug nidanib helps people with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and breathing problems. About 60 adults aged 40 and older with mild to moderate IPF will receive either…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated May 26, 2026 04:55 UTC
-
New pill for scarred lungs gets first human safety check
Disease control Not yet recruitingThis early-phase study tests whether a new tablet called HW241045 is safe for people. It involves 102 healthy volunteers aged 18 to 45. The goal is to find the right dose and check for side effects, as a first step toward treating idiopathic pulmonary fibrosis, a serious lung-sca…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Disease control
Last updated May 26, 2026 04:50 UTC
-
Could stem cells help scarred lungs? new trial begins
Disease control Not yet recruitingThis early-phase trial tests a stem cell product called REGEND007 for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. Twelve adults aged 40–80 will receive a single IV infusion to see if it is safe and tolerable. The st…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: EARLY_PHASE1 • Sponsor: Regend Therapeutics • Aim: Disease control
Last updated May 26, 2026 04:33 UTC
-
Inhaled stem cell particles aim to halt lung scarring in early trial
Disease control Not yet recruitingThis early study tests whether inhaling tiny particles from stem cells is safe for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Nine adults will receive the treatment twice daily for a week, and doctors will monitor sid…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE1 • Sponsor: Huan Ye • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New lung drug aims to outshine current treatment in major trial
Disease control Not yet recruitingThis study tests whether a new drug, deupirfenidone, works better than the current standard treatment (pirfenidone) at slowing lung function decline in adults with idiopathic pulmonary fibrosis (IPF). About 1,100 participants will take either drug three times daily for up to a ye…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE3 • Sponsor: PureTech • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Experimental therapy targets scar cells in fatal lung disease
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy for people with end-stage idiopathic pulmonary fibrosis (IPF), a severe lung scarring disease. The therapy uses specially engineered immune cells to target and calm the cells that cause scarring. The study will check if the treatmen…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
Talking their way to better health: video coaching for lung disease patients
Knowledge-focused Not yet recruitingThis study tests whether remote motivational interviewing (coaching via video calls) can improve self-care in 124 adults with idiopathic pulmonary fibrosis (IPF). Participants will use digital tools to learn better disease management, with researchers tracking changes in self-car…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated May 26, 2026 04:47 UTC
-
1,000-Patient study tests ancient herbal remedies for deadly lung disease
Knowledge-focused Not yet recruitingThis study will follow 1,000 people with idiopathic pulmonary fibrosis (IPF) to see if traditional Chinese medicine can reduce flare-ups and slow disease progression. Researchers want to find out which patients benefit most from this approach. The study does not test a new drug b…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Sponsor: Henan University of Traditional Chinese Medicine • Aim: Knowledge-focused
Last updated May 26, 2026 04:37 UTC
-
Massive study aims to decode lung disease patterns
Knowledge-focused Not yet recruitingThis study will observe nearly 3,000 people with idiopathic pulmonary fibrosis (IPF) to better understand how the disease progresses and how it relates to traditional Chinese medicine syndromes. Researchers will track lung function, exercise ability, and quality of life over time…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Sponsor: Henan University of Traditional Chinese Medicine • Aim: Knowledge-focused
Last updated May 26, 2026 04:36 UTC